HR4534-118

Passed House

To require a review of women and lung cancer, and for other purposes.

118th Congress Introduced Jul 11, 2023

Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.

Summary

What This Bill Does

This bill, To require a review of women and lung cancer, and for other purposes., changes federal law or congressional policy affecting federal agencies and legislative administrators. The main policy domain is Government Operations, Defense, Healthcare.

Who Benefits and How

federal agencies and legislative administrators may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.

Who Bears the Burden and How

federal implementing agencies may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.

Key Provisions

  • Section H2DE4245145FC417B89B27B46AEE88275: 1. Short title This Act may be cited as the Women and Lung Cancer Research and Preventive Services Act of 2024.
  • Section H71222605287B40C0A5802E5E9B13005B: 2. Interagency review to evaluate and identify opportunities for the acceleration of research on lung cancer in women and underserved populations, greater...

Evidence Chain:

This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.

At a Glance

What This Bill Does

This bill, To require a review of women and lung cancer, and for other purposes., changes federal law or congressional policy affecting federal agencies and legislative administrators.

Key Policy Areas

Government Operations, Defense, Healthcare

Primary Purpose

This bill, To require a review of women and lung cancer, and for other purposes., changes federal law or congressional policy affecting federal agencies and legislative administrators.

Policy Domains

Government Operations Defense Healthcare

Whole bill

Identified Gains
  • federal agencies and legislative administrators
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: eh
federal agencies and legislative administrators: ,
Identified Costs
  • federal implementing agencies
Model: codex-gpt-5 | Version: bill_summary_v2 | Source: eh
federal implementing agencies: ,

Legislative Progress

Passed House
Introduced Committee Passed
Dec 17, 2024

Received; read twice and referred to the Committee on Health, …

Jul 30, 2024

Additional sponsors: Ms. Pingree, Ms. Wasserman Schultz, Ms. Sewell, Ms. …

Jul 30, 2024

Reported with an amendment, committed to the Committee of the …

Jul 11, 2023

Mr. Boyle of Pennsylvania (for himself, Mr. Fitzpatrick, Ms. Blunt …

Jul 11, 2023 (inferred)

Passed House (inferred from eh version)

Stakeholder Effects

cui bono?

How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.

Government
9 mentions across 3 clauses
-9 negative

Department of Defense, Department of Health and Human Services, Department of Veterans Affairs

Health Care Services
3 mentions across 3 clauses
+3 positive

Lung cancer screening providers

Research & Science
2 mentions across 2 clauses
+2 positive

Medical researchers studying lung cancer

2/2
sections analyzed
Full impact breakdown

Bill Structure & Actor Mappings

Who is "The Secretary" in each section?

Domains
Government Operations Defense Healthcare
Actor Mappings
"secretary_of_defense"
→ Secretary of Defense
"secretary_of_health_and_human_services"
→ Secretary of Health and Human Services

We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.

Learn more about our methodology